Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diamthazole, also known as Dimazole, is an antifungal agent. It is an imidazole derivative that primarily acts by inhibiting the biosynthesis of ergosterol, a crucial component of fungal cell membranes. This disruption in ergosterol synthesis, along with effects on triglyceride and phospholipid synthesis, compromises the integrity and function of the fungal cell membrane. Additionally, it can lead to an intracellular accumulation of toxic hydrogen peroxide due to altered oxidative and peroxidative enzyme activities, contributing to cellular damage and necrosis. Diamthazole has also been observed to inhibit the transformation of Candida albicans blastospores into their invasive mycelial form. It has been used for research into infections, including cutaneous Trichophyton rubrum infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diamthazole.